The New Molecules Could Lead to Unique Treatments for Obesity, Diabetes, High Cholesterol, and Sleep Disorders
JUPITER, Fla., March 29, 2012 /PRNewswire-USNewswire/ -- Scientists from the Florida campus of The Scripps Research Institute have synthesized a pair of small molecules that dramatically alter the core biological clock in animal models, highlighting the compounds' potential effectiveness in treating a remarkable range of disorders—including obesity, diabetes, high cholesterol, and serious sleep disorders.
The study was published on March 29, 2012, in an advance, online edition of the journal Nature.
The study showed that when administered in animal models the synthetic small molecules altered circadian rhythm and the pattern of core clock gene expression in the brain's hypothalamus, the site of the master cellular clock that synchronizes daily rhythms in mammals; circadian rhythms are the physiological processes that respond to a 24-hour cycle of light and dark and are present in most living things.
When given to diet-induced obese mice, these same small molecules decreased obesity by reducing fat mass and markedly improving cholesterol levels and hyperglycemia—chronically high blood sugar levels that frequently lead to diabetes.
"The idea behind this research is that our circadian rhythms are coupled with metabolic processes and that you can modulate them pharmacologically," said Thomas Burris, a professor at Scripps Florida who led the study. "As it turns out, the effect of that modulation is surprisingly positive—everything has been beneficial so far."
Burris stressed that these compounds were first generation—the first to hit their targets in vivo with room for improvement as potential treatments. "In terms of therapeutics, this is really the first step," he said.
In the new study, the team identified and tested a pair of potent synthetic compounds that activate proteins called REV-ERB alpha and REV-ERB beta, which play an integral role in regulating the expression of core clock proteins that drive biological rhythms in activity and metabolism.
In the study, the scientists observed clear metabolic effects when the synthetic compounds were administered twice a day for 12 days. Animals displayed weight loss due to decreased fat mass with no changes in the amount of food they ate. The animals followed the human model of obesity closely, eating a standard Western diet of high fat, high sugar foods, yet still lost weight when given the compounds.
In one of the study's more striking findings, both synthetic compounds were shown to reduce cholesterol production. Cholesterol in the blood of treated animal models decreased 47 percent; triglycerides in the blood decreased 12 percent.
The circadian pattern of expression of a number of metabolic genes in the liver, skeletal muscle, and in fat tissue was also altered, resulting in increased energy expenditure, something of a surprise. In the study, the scientists observed a five percent increase in oxygen consumption, suggesting increased energy expenditure during the day and at night. However, these increases were not due to increased activity—the animals displayed an overall 15 percent decrease in movement during those same time periods.
In addition to its impact on metabolism, the two compounds also affected the animals' activity during periods of light and darkness, suggesting that this class of compound may be useful for the treatment of sleep disorders, including the common problem of jet lag.
The first authors of the study, "Regulation of Circadian Behavior and Metabolism by Synthetic REV‐ERB Agonists," are Laura A. Solt and Yongjun Wang of Scripps Research. Other authors include Subhashis Banerjee, Travis Hughes, Douglas J. Kojetin, Thomas Lundasen, Youseung Shin, Jin Liu, Michael D. Cameron, Romain Noel, Andrew A. Butler, and Theodore M. Kamenecka of Scripps Research; and Seung‐Hee Yoo and Joseph S. Takahashi of the Howard Hughes Medical Institute and University of Texas Southwestern Medical Center.
The study was supported by the National Institutes of Health and the Howard Hughes Medical Institute.
About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. Over the past decades, Scripps Research has developed a lengthy track record of major contributions to science and health, including laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. The institute employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
SOURCE The Scripps Research Institute